Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTreme neoadjuvant durvalumab + tremelimumab with gemcitabine + cisplatin in intrahepatic cholangiocarcinoma
2021-004411-11Phase 2Active
- Sponsor
- University Hospital Schleswig-Holstein
- Start
- Nov 2022
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by University Hospital Schleswig-Holstein. Primary endpoint: R0/R1-resection rates. Started Nov 2022; status: active.
02
Drugs
durvalumabtremelimumabgemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2021-004411-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004411-11.